Crucial US Expert Group to Vote on Modifying Newborn Hepatitis B Vaccine Guideline
Following a delay and an unusually contentious session, a federal vaccine advisory panel was set to cast ballots on Friday on whether to change the long-held guideline that every infant be inoculated against hepatitis B.
Fiery Exchange and a Deferred Vote
The opening session of the meeting on Thursday was marked by intense argument over restricting access to the hepatitis B vaccine for newborns and a choice to defer the vote by a day to provide committee members extra time to review the wording. The panel, which counsels the Centers for Disease Control and Prevention on vaccine use, had put off the vote twice in the past.
“Is there any specific evidence of harm of giving this vaccination before 30 days? Or is this conjecture?” questioned one committee member.
In reply, another attendee stated, “There is inadequate data about the long-term risk.”
Present Protocol and Possible Consequences
The shot is currently suggested for every newborn within 24 hours of delivery to stop transmission of hepatitis B, which can cause major damage to the liver. It has been given to more than a billion persons for in excess of thirty years.
The meeting in Atlanta presented no recent proof of damage attributable to the vaccine. Experts say any change to the existing hepatitis B immunization timeline could have major and extensive consequences for infant and child health in the United States.
Committee Makeup and Recent Changes
The expert committee can only make recommendations to the leader of the CDC. The group's roster has seen shifts in recent days, with the statement that the panel's latest chairman would leave for an formal position and be substituted with a heart specialist who has been questioning of other immunizations.
The board includes multiple vaccine skeptics who align with a goal to reform – and potentially, in some cases, eliminate – traditional immunization guidelines.
